Faeth Therapeutics, Inc.
FTH· Nasdaq
Released Mar 30, 2026, before the open
10-K filed Mar 30, 2026, 89 days after period end · 0001193125-26-132014
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$4.72M | -$7.77M | -$7.41M | -$12.23M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Faeth Therapeutics, Inc. · CIK 1829802 · Engraved from SEC EDGAR
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
ended Dec 31, 2025 · filed Mar 30, 2026 · 89 d after period end
7.8% from the close of Mar 27, 2026 to the close of Mar 30, 2026, the first after the release.